{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:24:31Z","timestamp":1760016271635,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.diagmicrobio.2020.115078","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:49:37Z","timestamp":1589190577000},"page":"115078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic"],"prefix":"10.1016","volume":"98","author":[{"given":"Stanley H.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0005","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0010","doi-asserted-by":"crossref","unstructured":"Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. CellPress Reviews, Trends in Immunology 2020 [in press].","DOI":"10.1016\/j.it.2020.04.008"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0015","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0020","unstructured":"NIAID News Release. Experimental HIV Vaccine Regimen Ineffective in Preventing HIV No Safety Concerns Found; NIH and Partners Discontinue Vaccinations. https:\/\/www.niaid.nih.gov\/news-events\/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv, released February 3, 2020."},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0025","unstructured":"NIH. NIH mobilizes national innovation initiative for COVID-19 diagnostics. NIH press release, April 29, 2020. At https:\/\/www.nih.gov\/coronavirus"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0030","article-title":"HIV vaccine efficacy trial preparations. 8th International Conference on AIDS","volume":"Vol 2","author":"Vermund","year":"1992"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0035","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0040","first-page":"147","article-title":"Laboratory detection of human retroviruses. In: AIDS and other manifestations of HIV infection, fourth edition, ed. Gary P. Wormser, Elsevier science, London","volume":"8","author":"Weiss","year":"2004","journal-title":"Chapter"},{"issue":"23","key":"10.1016\/j.diagmicrobio.2020.115078_bb0045","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1001\/jama.1985.03350470047010","article-title":"Screening for HTLV-III antibodies: the relation between prevalence and positive predictive value \u2013 reply","volume":"253","author":"Weiss","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.1985.03350260073029","article-title":"Screening test for HTLV-III (AIDS agent) antibodies: specificity, sensitivity and applications","volume":"253","author":"Weiss","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.diagmicrobio.2020.115078_bb0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(85)90261-2","article-title":"HLA-DR antibodies and HTLV-III antibody ELISA testing","volume":"2","author":"Weiss","year":"1985","journal-title":"Lancet"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320304545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320304545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:54:28Z","timestamp":1760003668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320304545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0732889320304545"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115078","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115078"}}